Li Yao-Dong, Ji Yu-Tong, Zhou Xian-Hui, Jiang Tao, Hong Yi-fan, Li Jin-Xin, Xing Qiang, Xiong Jian, Yusufuaji Yueerguli, Tang Bao-Peng
Department of Pacing and Electrophysiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China (mainland).
Clinical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China (mainland).
Med Sci Monit. 2015 May 16;21:1414-20. doi: 10.12659/MSM.894320.
Ivabradine is an inhibitor of mixed Na+-K+ current that could combine with HCN channels to reduce the transmembrane velocity of funny current (If), heart rate, and cardiac efficiency, and thus be used for the treatment of cardiovascular diseases such as chronic heart failure. As an ion channel blocker, Ivabradine is also a potential antiarrhythmic agent.
MATERIAL/METHODS: Twelve aging dogs (8-10 years old) underwent rapid atrial pacing for 2 months to induce age-related AF in this study. The dogs were randomly divided into the Ivabradine group and aging-AF group. The effects of Ivabradine on the electrophysiological parameters, including the effective refractory period (ERP) of the pulmonary veins and atrium, duration of AF, and inducing rate of AF, were investigated.
As compared to the aging-AF group, the ERPs of the left superior pulmonary vein (139.00±4.18 ms vs. 129.00±4.08 ms, P=0.005) and left auricle (135.00±3.53 ms vs. 122.00±4.47 ms, P=0.001) were significantly increased, while the duration of AF (46.60±5.07 s vs. 205.40±1.14 s, P=0.001) and inducing rate of AF (25% vs. 60%, P=0.001) were significantly decreased.
Ivabradine could effectively reduce the inducing rate of AF, and thus be used as an upstream drug for the prevention of age-related AF.
伊伐布雷定是一种混合钠钾电流抑制剂,可与超极化激活的环核苷酸门控通道(HCN通道)结合,降低起搏电流(If)的跨膜速度、心率和心脏效率,从而用于治疗慢性心力衰竭等心血管疾病。作为一种离子通道阻滞剂,伊伐布雷定也是一种潜在的抗心律失常药物。
材料/方法:本研究中,12只8至10岁的老龄犬接受了为期2个月的快速心房起搏以诱导与年龄相关的房颤。这些犬被随机分为伊伐布雷定组和老龄房颤组。研究了伊伐布雷定对电生理参数的影响,包括肺静脉和心房的有效不应期(ERP)、房颤持续时间和房颤诱发率。
与老龄房颤组相比,左上肺静脉的ERP(139.00±4.18毫秒对129.00±4.08毫秒,P = 0.005)和左心耳的ERP(135.00±3.53毫秒对122.00±4.47毫秒,P = 0.001)显著增加,而房颤持续时间(46.60±5.07秒对205.40±1.14秒,P = 0.001)和房颤诱发率(25%对60%,P = 0.001)显著降低。
伊伐布雷定可有效降低房颤诱发率,因此可作为预防与年龄相关房颤的上游药物。